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Abstract
Background: This study evaluated the benefits and impact of ICU therapeutic interventions on
the survival and functional ability of severe cerebrovascular accident (CVA) patients.
Methods:  Sixty-two ICU patients suffering from severe ischemic/haemorrhagic stroke were
evaluated for CVA severity using APACHE II and the Glasgow coma scale (GCS). Survival was
determined using Kaplan-Meier survival tables and survival prediction factors were determined by
Cox multivariate analysis. Functional ability was assessed using the stroke impact scale (SIS-16) and
Karnofsky score. Risk factors, life support techniques and neurosurgical interventions were
recorded. One year post-CVA dependency was investigated using multivariate analysis based on
linear regression.
Results:  The study cohort constituted 6% of all CVA (37.8% haemorrhagic/62.2% ischemic)
admissions. Patient mean(SD) age was 65.8(12.3) years with a 1:1 male: female ratio. During the
study period 16 patients had died within the ICU and seven in the year following hospital release.
The mean(SD) APACHE II score at hospital admission was 14.9(6.0) and ICU mean duration of stay
was 11.2(15.4) days. Mechanical ventilation was required in 37.1% of cases. Risk ratios were; GCS
at admission 0.8(0.14), (p = 0.024), APACHE II 1.11(0.11), (p = 0.05) and duration of mechanical
ventilation 1.07(0.07), (p = 0.046). Linear coefficients were: type of CVA – haemorrhagic versus
ischemic: -18.95(4.58) (p = 0.007), GCS at hospital admission: -6.83(1.08), (p = 0.001), and duration
of hospital stay -0.38(0.14), (p = 0.40).
Conclusion: To ensure a better prognosis CVA patients require ICU therapeutic interventions.
However, as we have shown, where tests can determine the worst affected patients with a poor
vital and functional outcome should treatment be withheld?
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Background
Cerebrovascular accidents (CVA) are currently the second
most common cause of mortality in the world, and
remain the most common cause of long-term disability in
adults [1-4]. New therapeutic methods are being
advanced to limit ischemic neuronal damage, although
their benefits are debatable [5-8]. The setting up of inten-
sive care units (ICU) for the treatment of acute CVAs has
caused controversy for many years [9-15], although new
evidence has established an increased patient survival rate
and quality of life in ICU treated patients compared to
those treated in medical departments [3,4,9-14]. CVA
patient admission into ICUs has now become routine, but
can not ensure better survival or provide less physical or
mental dependence for every patient. After suffering a cat-
astrophic neurological event the benefits of intensive care
remain controversial, and may only serve to prolong the
period before the patient's inevitable death [16].
The study aim was to predict the benefit and impact of
various ICU therapeutic interventions on the survival and
functional abilities of CVA patients who had suffered
severe ischemic or haemorrhagic stroke.
Methods
This study was conducted at the Hôtel-Dieu de France uni-
versity hospital in Beirut (Lebanon), linked to Saint-
Joseph University, which has 8 intensive care beds for
emergency and medical services.
A study was made of 62 ICU patients suffering from severe
ischemic or haemorrhagic CVA entering the ICU (via the
emergency or neurology departments, or other hospital
departments) over a retrospective period of 30 months
(July 2000 to January 2003) and 12 months prospectively
(January 2003 to January 2004). Exclusion criteria
included patients who had suffered from sub-arachnoidal
haemorrhage, extra-dural haematoma or transient
ischemic attack.
CVA severity was measured using an acute physiology, age
and chronic health evaluation (APACHE II: range 0 to 71)
[17] and a Glasgow coma scale (GCS: range 3 to 15) neu-
rological assessment [18,19] at admission, 48 hours after
admission and at ICU discharge. Patient survival was
determined using Kaplan-Meier survival tables. The
patients' state of dependence and functional abilities were
measured using stroke impact scale-16 (SIS-16) [20,21],
which provides a measurement of a patient's capacity to
perform daily activities. Additionally, their general health
status was assessed using a Karnofsky Score (range 0 to
100) [22,23] before ICU admission, at hospital discharge,
and at 3 months and 1 year post-CVA.
Continuous variables were expressed as means with their
standard deviation (SD), whereas categorical variables
were expressed as actual numbers and percentages. For
quantitative variables, a student t-test was used to com-
pare the means of two categories. For more than two cate-
gories, an analysis of variance was used, and if there were
statistically significant differences a post-hoc test was per-
formed. Categorical variables were analyzed using a Chi-
square test. A repeated-measures ANOVA was made to
study the evolution of quantitative variables over time,
and a Spearman correlation was used to study the rela-
tionship between neurological and general health severity
scores.
Determination of independent variables predicting a CVA
patient's physical dependency at discharge and after one
year was made using a univariate analysis, supplemented
by a multivariate linear regression.
Survival analysis tables were used to assess CVA patient
survival. Univariate qualitative variables were compared
using the log rank method. A multivariate analysis of sur-
vival predictive factors was made using the Cox propor-
tional hazards technique. All predictive factors with a
univariate p < 0.1 were entered in the multivariate model.
To adjust for testing multiple hypotheses we performed
the Holm stepdown Sidak procedure for multiple com-
parisons (P' sds). All other tests were considered statisti-
cally significant for a p-value < 0.05.
The statistical software used in this study was SPSS v13
(SPSS Inc, Chicago, Illinois).
Results
Of the 62 patients studied, 47 (75.8%) came from the
emergency department, 5 (8.1%) from the neurology
department, 5 (8.1%) came from other medical depart-
ments within the hospital and 5 (8.1%) were transferred
from another hospital. The male: female ratio was 1:1
with a mean (SD) age of 65.8 (12.3) years.
Thirty three patients (53.2%) suffered from embolic CVA,
17 (27.4%) from haemorrhagic CVA and 12 (19.4%)
from thrombotic CVA. Half the CVA cases were in the
carotid artery territory, 33.9% were in the vertebro-basilar
artery territory and the remaining cases were in the cortical
and subcortical areas. Risk factors (infection and cardiac
problems) were identical for both ischemic and haemor-
rhagic stroke, except for atrial fibrillation which was
found in 12 patients with ischemic stroke (p < 0.001).
At admission the mean APACHE II values, Karnofsky
score and the SIS-16/80 were 14.90 (6.0), 91.50 and
74.93 respectively, which indicated a good initial func-
tional state. The majority of patients were completelyBMC Neurology 2008, 8:24 http://www.biomedcentral.com/1471-2377/8/24
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independent with an average Karnofsky score higher than
90 for both ischemic and haemorrhagic CVA. The GCS/15
at admission had a mean of 9.9.
A univariate comparison between survivors and non-sur-
vivors with respect of all risk factors studied was made and
is presented in Table 1. Continuous normal data are rep-
resented as mean(SD), continuous non-normal data and
ordinal data are represented as median (1st–3rd quartile)
and categorical data are represented as frequencies.
The ICU interventions and their significance in treating
ischemic and haemorrhagic CVA are presented in Table 2.
Additionally, it was found that; 10 (16.1%) patients in the
ischemic group received thrombolysis, 34 (54.8%) had
received a naso-gastric tube to avoid difficulties in swal-
lowing, 23 (37%) underwent mechanical ventilation and
five patients (8.1%) underwent surgical intervention.
A receiver operating characteristic curves (ROC) was plot-
ted for APACHE II and GCS; the area under the ROC curve
was 0.834 (95% CI: 0.722 to 0.946) (p < 10-3) for
APACHE II and 0.828 (95% CI: 0.715 to 0.940) (p < 10-3)
for GCS. When the APACHE II and GCS curves are com-
pared, the area under the ROC curve of APACHE II
showed no significant differences in p-values. (Fig. 1).
Table 1: Univariate comparison between survivors and non-survivors with respect of all risk factors studied
Survivors (n = 46) Non survivors (n = 16) p-value P' sds
Age (years) 63.9 ± 11.7 71.1 ± 13.0 0.043 0.681
Female gender 50.0% 50.0% 0.999 1.000
Hypertension 71.7% 56.3% 0.254 0.995
Diabetes mellitus 23.9% 37.5% 0.294 0.996
Dyslipidemia 28.3% 12.5% 0.205 0.990
COPD 2.2% 0.0% 0.999 1.000
Myocardial infarction 10.9% 18.8% 0.418 0.999
CABG 4.3% 6.3% 0.999 1.000
Cardiac failure 6.5% 25.0% 0.044 0.675
Atrial fibrillation 17.4% 25.0% 0.507 0.999
Renal failure 19.6% 12.5% 0.524 0.999
Cancer 2.2% 6.3% 0.453 0.999
Smoking 30.4% 12.5% 0.158 0.977
Hemorrhagic stroke 26.1% 31.3% 0.690 0.999
Previous stroke 26.1% 25% 0.932 1,000
Thrombolysis 21.7% 0% 0.042 0.712
Karnofsky score on admission 100 (100–100) 80 (80–100) 0.029 0.621
SIS 16/80 score on admission 80 (80–80) 80 (70–80) 0.290 0.997
Apache score on admission 13 (10–16) 20 (18–23) < 0.001 0.037
GCS score on admission 11 (9–13) 6 (4–10) < 0.001 0.036
Apache score after 48 hours 12 (8–18) 19 (17–24) 0.003 0.097
GCS score after 48 hours 12 (9–14) 8 (4–11) 0.001 0.035
Sedative treatment 4.3% 25.0% 0.034 0.669
Anti-hypertensive treatment 65.2% 75.0% 0.471 0.999
Anti-coagulant treatment 78.3% 62.5% 0.215 0.990
Anti-epileptic drugs 15.2% 37.5% 0.059 0.768
Diuretics 17.4% 438% 0.034 0.658
Corticosteroids 13.0% 0.0% 0.325 0.997
Gastric tube 43.5% 87.5% 0.002 0.068
Surgery 4.3% 18.8% 0.103 0.918
Infection 43.5% 62.5% 0.190 0.988
Cardiac complications 19.6% 25.0% 0.646 0.999
Tracheostomy 10.9% 6.3% 0.999 0.999
Respiratory physiotherapy 15.2% 6.3% 0.357 0.998
Mechanical ventilation duration 9 (8–13) 5 (2–16) 0.554 0.998
ICU length of stay 4 (2–12) 9 (4–21) 0.042 0.699
Apache score on ICU discharge 10 (5–14) 16 (15–20) 0.040 0.706
GCS score on ICU discharge 13 (11–15) 11 (8–11) 0.042 0.686
COPD: Chronic obstructive pulmonary disease; CABG: Coronary artery bypass grafting. GCS: Glasgow coma scale. ICU: Intensive care unit. 
Continuous normal data are represented as mean ± standard deviation. Continuous non normal data and ordinal data are represented as median 
(1st quartile – 3rd Quartile); Categorical data are represented as frequencies (Percentage). P'sds is the adjusted P value derived from the Holm-Sidak 
step-down procedure to correct for multiple comparisons.BMC Neurology 2008, 8:24 http://www.biomedcentral.com/1471-2377/8/24
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Disability assessments
The GCS/15 was used to assess the depth and duration of
a patient's coma and impaired consciousness (Figure 2).
Results showed (*) a slow increase after admission and
then a major increase between 48 hours post-CVA and
ICU departure. After discharge from hospital there was a
continuous but less marked improvement in the GCS.
The SIS-16 was used to provide an indication of a patient's
state of dependency (Figure 3). Results showed (*) a
strong improvement after hospital departure and in the
three months following, although this improvement was
less pronounced later. The Karnofsky score, which was
used to give an indication of the patient's functional sta-
tus, showed a similar evolution to the SIS-16 for both
types of CVA.
Univariate analysis indicated that the patient's functional
state (SIS-16) at discharge from hospital was influenced
by age, GCS at hospital admission, type of CVA and dura-
tion of hospital stay, whereas other variables had little
influence. Multivariate analysis incorporating linear
regression was used to determine the definitive significant
factors (Table 3).
One year after discharge, disability was essentially related
to the SIS-16 at hospital discharge (Odds ratio (OR):
0.734(0.082) for ischemic and 0.374(0.024) for haemor-
rhagic stroke). Complementary factors in the ischemic
group were: patient age (OR: -0.534(0.190)), mechanical
ventilation (OR: -10.921(5.238)) and diabetes mellitus
(OR: 16.043(4.547)). Complementary factors in the
haemorrhagic group were: arterial hypertension (OR: -
The Glasgow Coma Scale (GCS/15) Figure 2
The Glasgow Coma Scale (GCS/15)
Table 2: The number and percentage of ICU interventions for ischemic and haemorrhagic CVA and their significance (p-value)
Intervention Ischemic Haemorrhagic p-value P' sds
N% N %
Sedation 2 4.45 4 23.53 0.043 0.296
Anti-hypertensives 28 62.22 14 82.35 0.223 0.717
Anti-coagulants 42 93.33 4 23.53 0.001 0.011
Anti-epileptics 4 8.89 9 52.94 0.001 0.010
Osmotic diuretics 8 17.78 7 41.18 0.094 0.499
Steroids 4 8.89 2 11.76 0.662 0.987
Nasogastric tube 22 48.89 12 70.59 0.159 0.646
Surgery 1 2.22 4 23.52 0.018 0.151
Mechanical ventilation 16 35.56 7 41.18 0.771 0.988
Infections 21 46.67 9 52.94 0.778 0.951
Cardiac complications 10 22.22 3 17.64 1.000 1.000
P' sds is the adjusted p value derived from the Holm step-down Sidak procedure for multiple comparisons.
Receiver operating characteristic curves (ROC) for APACHE  II and GCS at admission Figure 1
Receiver operating characteristic curves (ROC) for 
APACHE II and GCS at admission.BMC Neurology 2008, 8:24 http://www.biomedcentral.com/1471-2377/8/24
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13.394(0.938)), mechanical ventilation (OR:
16.663(1.211)) and naso-gastric intubation (OR:
24.301(1.112)).
Survival
Among the 62 patients studied, 16 (25.8%) died in the
ICU and seven died in the year following hospital dis-
charge. For the study period a Kaplan-Meier plot (Figure
4) showed a steady decline in patient numbers up to Day
100 with no further decline up to day 1000. The signifi-
cant factors determined by univariate analysis influencing
survival were: patient age, history of smoking and cardiac
insufficiency, delay between onset of symptoms and ICU
admission, APACHE II and GCS at hospital admission,
hospital length of stay, thrombolysis, and the require-
ment for sedation, anti-epileptic treatment, osmotic diu-
resis, naso-gastric intubation, mechanical ventilation and
surgery.
To evaluate the impact of "duration of ventilation" on
prognosis, we divided this variable into 3 class categories;
0: no ventilation; 1: ventilation < 72 hours (short) and 2:
ventilation > 72 hours (long). Univariate analysis of ven-
tilation confirmed a bad prognosis with a risk ratio (RR)
of 2.65 (95% CI: 1.55 to 4.55; p < 10-3). Multivariate
analysis using a Cox regression provided the three final
independent variables shown below (Table 4). Using a
multivariate analysis we also examined the effect of each
day of mechanical ventilation on worsening the CVA
patients' prognosis (Table 4).
Discussion
Although the development of new stroke units and treat-
ment modalities have reduced the disabilities and mortal-
ities caused by acute severe strokes, the real clinical
benefits for the most severely affected group of patients
remain highly speculative. This study analyzed the bene-
fits and implications of the therapeutic resources used in
treating critical stroke patients (ischemic and haemor-
rhagic) in respect to their survival and functional abilities.
Disability was measured by the ordinal variable SIS-16,
but was better predicted by linear regression. Prognosis
was studied by taking into consideration both the time
factor and Kaplan-Meier survival tables.
For the study period, severe stroke accounted for 7% of
medical ICU admissions and 17.5% of all hospital stroke
cases. The decision to admit a patient into the ICU was
determined primarily by their level of consciousness, and
for the urgency to use intensive therapeutic procedures,
such as mechanical ventilation, sedation, anti-epileptics,
diuretics, osmotic or steroid treatment and surgical inter-
ventions. Pre-stroke the patients were completely inde-
pendent with a Karnofsky score higher than 90 for both
types of CVA. After examining the GCS on admission, we
found an average score of less than 10 for both ischemic
and haemorrhagic CVAs, which had probably influenced
their ICU admission [24]. Once admitted, patients under-
went intensive therapeutic procedures such as; thrombol-
ysis, unblocking respiratory airways, mechanical
ventilation, haemodynamic monitoring and treatment for
intracranial hypertension.
Taking ICU admission as our starting point, important
differences were noted between ischemic and haemor-
rhagic CVA. All risk factors, excluding atrial fibrillation,
were identical in the two types of CVA [25,26]. We found
that ischemic CVA was better tolerated as haemorrhagic
CVA patients frequently required sedation in order to
administer anti-epileptic treatment, surgical interven-
tions, or osmotic diuretics. On admission the level of con-
sciousness measured by the GCS was lower in ischemic
Table 3: Factors that influence a patient's functional state and dependency at discharge from hospital; multivariate analysis
Linear coefficient Standard Error p-value
(constant) 14.991 12.425 0.273
GCS at admission 6.833 1.077 0.001
Type of CVA Haemorrhagic vs Ischemic -18.954 4.579 0.007
Duration of hospital stay (day) -0.378 0.144 0.040
The Stroke Impact Scale 16 (SIS-16) Figure 3
The Stroke Impact Scale 16 (SIS-16)BMC Neurology 2008, 8:24 http://www.biomedcentral.com/1471-2377/8/24
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CVA than in haemorrhagic CVA cases, and displayed a
major increase between 48 hours post-CVA and ICU
departure [27,28]. As previously seen in other studies
[24,26,29-31] a strong improvement in functional ability
(SIS-16/80) was noted after hospital departure and in the
following 3 months, although this improvement was less
pronounced at later times.
There are several factors that can predict the dependency
status at hospital discharge, of these haemorrhagic CVA
with a low level of consciousness on admission and a
longer duration of hospital stay is associated with the
worst functional ability. Moreover, on admission a severe
haemorrhagic CVA with a GCS of 7 has more than 30
points less in the SIS-16 score at discharge than a severe
ischemic CVA with a GCS of 9. Severe disability was iden-
tified in 40.5% of surviving patients on discharge, which
decreased after one year to 24%. This result confirms the
Barthel Index results of Navarrete-Navarro et al. [24], who
showed that 26 % of severe stroke patients had a poor out-
come and a severe functional disability after one year.
Measuring neurological severity at hospital admission by
GCS is the main determinant of future functional capacity
in CVA patients at discharge and after one year. Indeed,
although the patients' functional ability had improved
after one year, it would be best predicted by their func-
tional ability at discharge. Surviving severe stroke patients
increase the burden of the disease, due to their health care
utilization, which necessitates acute care, rehabilitation
and an increased discharge rate to nursing homes, which
all contribute to the increased cost of the disease
[24,27,32,33].
Three independent factors contribute to the survival out-
come of severe stroke patients. Of these, the decreased
level of consciousness evaluated by GCS is the most
important determinant of increased mortality. Mortality
risk increases by 20% for each unit decrease in the GCS.
Previous studies have confirmed the mortality prediction
value of the GCS at admission, 30 days [28,34] and one-
year later [24]. Moreover, a low GCS at admission coupled
with an absence of pupillary light response corresponds to
a poorer prognosis for survival [28].
Prognostic scoring systems such as APACHE can provide
initial risk stratification for severely ill hospitalized
patients. Studies have shown [17,24] that APACHE can
predict survival outcome independently. Scoring the
severity of the neurological disease and the severity of the
patients general health status on admission are both good
survival rate predictors in severe stroke patients [24].
Endotracheal intubation and the necessity to apply
mechanical ventilation in severe stroke patients for neuro-
logical reasons are accompanied by the worst prognosis.
Many studies have shown that stroke patients requiring
mechanical ventilation have a bad outcome and surviving
patients remain deeply disabled [28,34-37]. Santoli et al.
showed that an assessment of brain stem reflexes might
help identify the subgroup of patients with a high proba-
bility of death despite mechanical ventilation [36]. More-
over, a short duration of mechanical ventilation (< 72
hours) is still a bad predictor of survival with a risk ratio
of 2.45 (95% CI: 1.36 to 4.43; p < 0.003). No difference
between ischemic and haemorrhagic stroke patients was
noted in terms of duration and requirement for mechani-
Table 4: Cox model for predicting survival
Consideration Risk Ratio 95% CI p-value
Classes of mechanical ventilation GCS at hospital administration 0.79 0.66 to 0.95 0.012
APACHE II at hospital admission 1.12 1.00 to 1.26 0.049
Duration of mechanical ventilation (categorical) 2.45 1.36 to 4.43 0.003
Number of days on mechanical ventilation GCS at hospital admission 0.80 0.66 to 097 0.024
APACHE II at hospital admission 1.12 1.00 to 1.24 0.050
Duration of mechanical ventilation (days) 1.07 1.01 to 1.15 0.046
Kaplan Meier survival curve for severe stroke patients Figure 4
Kaplan Meier survival curve for severe stroke 
patientsBMC Neurology 2008, 8:24 http://www.biomedcentral.com/1471-2377/8/24
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cal ventilation. Indeed, when we looked at the ICU inter-
ventions our results revealed (Table 2) that all these
factors were uninfluenced by the cause of the patients'
CVA.
Conclusion
When poorly selected patients are admitted into an ICU,
inappropriate use of technology may not save lives, nor
improve the quality of life, but rather transform dying
into a prolonged, miserable and undignified process. We
have shown that several factors and their assessments can
help to identify the subgroup of patients that have an
acutely reversible medical condition and are liable to have
a potentially good functional recovery, from those that
may suffer a prolonged and drawn out death regardless of
any medical intervention. This raises important ethical
questions: is it permissible to select certain patients for
medical interventions and resources, and to condemn
others to death without trying to intervene? Or, do these
interventions constitute a therapeutic relentlessness that is
an indispensable necessity?
The size of the cohort was limited as this study was con-
ducted in only one centre over a 30 month period. There-
fore, further studies involving a greater number of patients
are urgently needed in order to shed some light on theses
ethical and economical considerations.
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